The Study, Published in the American Journal of Therapeutics, Also Shows That COLD-EEZE(R) Treatment Reduces Antibiotic Use
DOYLESTOWN, Pa., Nov. 21 /PRNewswire-FirstCall/ -- The results of an independent study, released this week in the November/December issue of the American Journal of Therapeutics, find that COLD-EEZE(R), manufactured and distributed by The Quigley Corporation (Nasdaq: QGLY), is an effective means of cold prevention. Study findings show that, when taken daily, COLD-EEZE's patented Zinc Gluconate Glycine formula statistically lessens the number of colds an individual suffers per year, reducing the incidence from 62% to 28%.
"Up until now, prevention of the common cold has never been established," said Dr. Betty McElroy, Medical Director at the Heritage School where the study was conducted. "We didn't set out to complete a clinical study, but after witnessing firsthand the efficacy of COLD-EEZE to treat symptoms, we decided to report our findings. We were later pleased to discover that COLD- EEZE was also an effective means of cold prevention when taken once daily."
These findings are the result of an independent analysis of three years of clinical data at the Heritage School facility in Provo, Utah. The study also finds that, when COLD-EEZE is taken as a first-line treatment for the common cold, it statistically reduces the use of antibiotics for respiratory illnesses by 92%. Additionally, the study findings reinforce the original clinical trials, concluding that COLD-EEZE reduces the median duration of a cold by approximately 4 days from 10 to 6 days.
"While antibiotics should be used to treat bacterial infections, they are not effective against viral infections like the common cold, most sore throats, and the flu," remarked Dr. McElroy. "The results of this study show that the public has an effective, over-the-counter, cost-effective alternative for the common cold."
"We are very excited to have this data from the Heritage Study," said Guy Quigley, president and CEO of The Quigley Corporation. "These findings reinforce what we have been hearing for years from consumers -- that COLD- EEZE, if taken once daily in the place of a zinc supplement, seems to lessen the amount of common colds."
Synergy Research Inc., an independent research organization, conducted the retrospective study comprised of more than 170,000 patient days on a student population of 378 adolescents ranging in age from 12 to 18 years. The average length of stay at Heritage School is 14 months.
The Heritage School introduced COLD-EEZE lozenges to aid in the relief of the common cold in response to the high incidence of colds in 1999. COLD-EEZE was administered symptomatically to treat common cold signs and symptoms in September 1999 and became standard practice at the facility in December 2000. Between December 2000 and May 2001, one dose of COLD-EEZE was administered daily to the Heritage School students. Medical statistics then showed a decrease in cold episodes and the findings were reported to The Quigley Corporation.
COLD-EEZE is the #1 pharmacist recommended zinc treatment. It is recommended nine-to-one over its nearest competitor (Pharmacy Times survey, 1998-2002). The Quigley Corporation (Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the COLD-EEZE family of patented Zinc Gluconate Glycine (ZIGG) lozenges, gums and sugar-free tablets. COLD-EEZE is the only lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, un certainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward- looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.